Australian media has recently reported on a poster presented at the 29th International Symposium on ALS/MND held in Glasgow in December that reported outcomes of a phase 1 Clinical Trial conducted in Australia. The phase 1 trial was designed to test the safety and dosage of the compound CuATSM and research funds donated to MND NSW have been part of the $1.2million invested in trials of copper ATSM through the MND Research Institute of Australia.
A hypothesis adding another small piece to the MND jigsaw featured on the ABC radio AM program yesterday and on some news channels in Australia last night. The story briefly explored a review article about fungal neurotoxins and sporadic motor neurone disease, published this month in the journal Neurotoxicity Research.
A big thank you to Tony Calleja who raised $1,390 from a raffle in support of MND NSW as part of his fundraising 'The Lap of Honour 2018'. Thank you to everyone who supported Tony with a ticket purchase and congratulations to the winners! Pictured left is Tony at one of his raffle ticket sale locations.
We are excited to announce MND NSW has been selected as the winner of the Disability Services Consulting (DSC) 2018 Provider Awards in the category NDIS Transition for our proactive and progressive approach to solving NDIS challenges. Thank you to Karen Dempsey of Epic Rehab for our nomination and thank you to DSC for this Award.
